These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25901479)

  • 1. Effect of dosing interval on pharmacokinetics of fentanyl pectin nasal spray from a crossover study.
    Chen C; Bujanover S; Gupta A
    J Opioid Manag; 2015; 11(2):139-46. PubMed ID: 25901479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacokinetic assessment of an alternate titration strategy for fentanyl pectin nasal spray.
    Perelman M; Knight A
    Int J Clin Pharmacol Ther; 2013 Dec; 51(12):942-7. PubMed ID: 24120713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and relative bioavailability of fentanyl pectin nasal spray 100 - 800 µg in healthy volunteers.
    Fisher A; Watling M; Smith A; Knight A
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):860-7. PubMed ID: 21084042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
    Darwish M; Tempero K; Kirby M; Thompson J
    Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers.
    Darwish M; Kirby M; Robertson P; Tracewell W; Jiang JG
    Clin Ther; 2006 May; 28(5):707-14. PubMed ID: 16861092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic comparisons of three nasal fentanyl formulations; pectin, chitosan and chitosan-poloxamer 188.
    Fisher A; Watling M; Smith A; Knight A
    Int J Clin Pharmacol Ther; 2010 Feb; 48(2):138-45. PubMed ID: 20137766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain.
    Taylor D; Radbruch L; Revnic J; Torres LM; Ellershaw JE; Perelman M
    J Pain Symptom Manage; 2014 Jun; 47(6):1001-7. PubMed ID: 24128821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain.
    Radbruch L; Torres LM; Ellershaw JE; Gatti A; Luis Lerzo G; Revnic J; Taylor D
    Support Care Cancer; 2012 Mar; 20(3):565-73. PubMed ID: 21424794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of allergic rhinitis and its treatment on the pharmacokinetics of nasally administered fentanyl.
    Perelman M; Fisher AN; Smith A; Knight A
    Int J Clin Pharmacol Ther; 2013 May; 51(5):349-56. PubMed ID: 23458227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-dose pharmacokinetics of fentanyl sublingual spray and oral transmucosal fentanyl citrate in healthy volunteers: a randomized crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Ther; 2013 Mar; 35(3):236-43. PubMed ID: 23497761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain.
    Lennernäs B; Hedner T; Holmberg M; Bredenberg S; Nyström C; Lennernäs H
    Br J Clin Pharmacol; 2005 Feb; 59(2):249-53. PubMed ID: 15676050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.
    Parikh N; Goskonda V; Chavan A; Dillaha L
    Clin Drug Investig; 2013 Jun; 33(6):391-400. PubMed ID: 23605506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study.
    Finn AL; Vasisht N; Stark JG; Gever LN; Tagarro I
    Clin Drug Investig; 2012 Jan; 32(1):63-71. PubMed ID: 22128878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety, tolerability, and consistency of effect of fentanyl pectin nasal spray for breakthrough cancer pain in opioid-tolerant patients.
    Portenoy RK; Raffaeli W; Torres LM; Sitte T; Deka AC; Herrera IG; Wallace MS;
    J Opioid Manag; 2010; 6(5):319-28. PubMed ID: 21046929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain.
    Kaasa S; Moksnes K; Nolte T; Lefebvre-Kuntz D; Popper L; Kress HG
    J Opioid Manag; 2010; 6(1):17-26. PubMed ID: 20297611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study.
    Fallon M; Reale C; Davies A; Lux AE; Kumar K; Stachowiak A; Galvez R;
    J Support Oncol; 2011; 9(6):224-31. PubMed ID: 22055892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose proportionality of fentanyl buccal tablet in doses ranging from 600 to 1300 microg in healthy adult subjects: a randomized, open-label, four-period, crossover, single-centre study.
    Darwish M; Kirby M; Robertson P; Tracewell W; Xie F
    Clin Drug Investig; 2010; 30(6):365-73. PubMed ID: 20441245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Comparative Study.
    Mercadante S; Aielli F; Adile C; Costanzi A; Casuccio A
    J Pain Symptom Manage; 2016 Jul; 52(1):27-34. PubMed ID: 27208863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.